Clinical trials are underway in South Korea to test the safety and efficacy of two vaccine candidates, including INO-4800 developed by Inovio Pharmaceuticals. The International Vaccine Institute (IVI), headquartered in Seoul, has won approval to test the safety and efficacy of IN0-4800 at Seoul National University (SNU) Hospital, a prominent state hospital in South Korea.
"In order to develop vaccines, active participation of healthy applicants is important," said Choe Pyeong-gyun, an SNU Hospital professor of infectious disease. INO-4800 would be administered to 40 people aged 19 to 50 to verify safety. The hospital will acquire immune response data in an experiment on 120 people.
Inovio has promoted INO-4800 as a promising COVID-19 vaccine candidate. The company has assembled a global coalition of collaborators, partners and funders to rapidly advance INO-4800.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.